A Review of a Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes

This publication is sponsored by Insulet Corporation.

This Clinical Brief provides key information regarding the results of a pivotal clinical trial of a tubeless, on-body automated insulin delivery system in pediatric and adult patients with type 1 diabetes. An interview with trial investigators offers insights on the impact of advances in technology on disease management and treatment.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

A Review of a Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes

Trending on AJMC

GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

A Review of a Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes

Trending on AJMC

GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial